

WEDNESDAY 7th May 2014 COMMENCING 10.30 AM
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0514

***To protect commercial confidentiality, the first appraisal will be conducted in private.
The final appraisal recommendation will be announced in public***

5. **Appraisal 1 - Full Submission (PAS)**
Abiraterone acetate (Zytiga[®]) in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

2/AWMSG/0514
Appendices

The meeting will now open to the public (approx 11.15 am)

6. **Chairman's report (verbal update)**
7. **Appraisal 2 - Full Submission**
Fluticasone furoate/vilanterol (as trifenate) (Relvar[®] Ellipta[®]) for the symptomatic treatment of adults with chronic obstructive pulmonary disease, with a FEV₁ < 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy
8. **One System for Health**

3/AWMSG/0514
Appendices

4/AWMSG/0514

Date of next meeting:
Wednesday 11th June 2014 in Cardiff